Chronic renal insufficiency: A diagnostic and therapeutic approach

Archives of Internal Medicine

Volumn 158, Issue 16, 1998, Pages 1743-1752

  Rahman, Mahboob ^b   Smith, Michael C ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANGIOTENSIN; ANTINUCLEAR ANTIBODY; CALCIUM; CATECHOLAMINE; CIMETIDINE; COMPLEMENT; CONTRAST MEDIUM; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHORUS; PIROXICAM; POTASSIUM; PROTEIN; SULINDAC; THIAZIDE DIURETIC AGENT; TRIMETHOPRIM; VASOPRESSIN; VITAMIN D;

ANTIBODY DETECTION; BLOOD GLUCOSE MONITORING; CHRONIC KIDNEY FAILURE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CROSS REACTIVITY; ELECTROLYTE DISTURBANCE; FLUID BALANCE; HEALTH CARE COST; HUMAN; KIDNEY FUNCTION TEST; KIDNEY SIZE; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEIN URINE LEVEL; REVIEW; VITAMIN D METABOLISM;

HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 0032517061     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.16.1743     Document Type: Review

References (147)

1. US Renal Data System. USRDS 1996 Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1996.
2. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 1990;38:167-184.
3. Shemesh O, Goldbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28: 830-838.
4. Mitch WE, Walser M, Buffington GA, Lemann J. A simple method for estimating progression of chronic renal failure. Lancet. 1976;2:1326-1328.
5. Shah BV, Levey AS. Spontaneous changes in the rate of decline in reciprocal serum creatinine: errors in predicting the progression of renal disease from extrapolation of the slope. J Am Soc Nephrol. 1992;2:1186-1191.
6. Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F. Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther. 1978;24:76-83.
7. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine of man. J Urol. 1975;114: 802-808.
8. Schwartz WB, Kassirer JP. Medical management of chronic renal failure. Am J Med. 1968; 44:786-801.
9. Murray T, Goldberg M. Chronic interstitial nephritis: etiologic factors. Ann Intern Med. 1975; 82:453-459.
10. Kasinath BS, Mujais SK, Spargo BH, Kate AI. Non-diabetic renal disease in patients with diabetes mellitus. Am J Med. 1983;75:613-623.
11. Parving HH, Gall MA, Skott P, et al. Prevalence and causes of albuminuria in noninsulin dependent diabetic patients. Kidney Int. 1992;41:758-762.
12. Chihara J, Takebayeshi S, Taguchi T, Yokoyama K, Harada T, Naito S. Glomerulonephritis in diabetic patients and its effect on the prognosis. Nephron. 1986;43:45-49.
13. Analgesics and the kidney: summary and recommendations to the scientific advisory board of the National Kidney Foundation from an ad hoc committee of the NKF. Am J Kidney Dis. 1996; 27:162-165.
14. Freedman BI, Iskander S, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis. 1995;25:207-221.
15. Rostand GS, Brown G, Kirk KA, Rutzky EA, Dustan HP. Renal insufficiency in treated hypertension. N Engl J Med. 1996;320:684-688.
16. Walker WG. Hypertension related renal injury: a major contributor to end stage renal disease. Am J Kidney Dis. 1993;22:164-173.
17. Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease Trial. Kidney Int. 1997;51:244-252.
18. Appel RG, Bleyer M, Reasis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int. 1995;48: 171-176.
19. Almeida JB, Saragoca MA, Tavares A, Cezareti ML, Draibe SA, Ramos OL. Severe hypertension induces disturbances of renal autoregulation. Hypertension. 1992;19:11279-11283.
20. Parving HH, Kastrup H, Smidt UM, Anderson AD, Feldt-Rasmussen B, Sandah-Christiansen J. Impaired autoregulation of GFR in type 1 (insulin dependent) patient with nephropathy. Diabetologica. 1984;27:547-552.
21. Brown SA, Finco DR, Navar LG. Impaired renal autoregulatory ability in dogs with reduced renal mass. J Am Soc Nephrol. 1995;5:1768-1774.
22. Danovitch GM, Bourgoignie J, Bricker NS. Reversibility of the salt losing tendency of chronic renal failure. N Engl J Med. 1977;296:14-19.
23. Cody RI, Ljungman S, Corit AB. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int. 1988;34:361-367.
24. Oster JR, Materson BI. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin converting enzyme inhibitors. Arch Intern Med. 1992;152: 704-710.
25. Rose BD. Diuretics. Kidney Int. 1991;39:336-352.
26. Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70: 234-239
27. Packer M, Lee WH, Medina V, Yushak M. Influence of renal function on the hemodynamic and clinical response to long term captopril therapy in severe chronic heart failure. Ann Intern Med. 1986;104:147-154.
28. Toto RD, Mitchell HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med. 1991;115: 513-519.
29. Papadakis MA, Wexman MP, Fraser C, Sedlacek SM. Hyperkalemia complicating digoxin toxicity in a patient with renal failure. Am J Kidney Dis. 1985;5:64-66.
30. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-869.
31. Turka LA. Urinary tract obstruction. In: Rose BD, ed. Pathophysiology of Renal Disease. New York, NY: McGraw-Hill Book Co; 1987:447-468.
32. Klahr S. Pathophysiology of obstructive nephropathy. Kidney Int. 1983;23:414-426.
33. Finberg M, Hillman B, Smith EH. Ultrasound in the evaluation of the nonfunctioning kidney. In: Rosenfield AT, ed. Genitourinary Ultrasonography. New York, NY: Churchill Livingstone Inc; 1979:105.
34. Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papiledema. QJM. 1958;27:117-154.
35. Mitchell HC, Graham RM, Pettinger WA. Renal function during long term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. Ann Intern Med. 1980; 93:676-681.
36. Luft FC, Block R, Szwed JJ, Grim CM, Grim CE. Minoxidil treatment of malignant hypertension. JAMA. 1978;240:1985-1987.
37. Humes D. Aminoglycoside nephrotoxicity. Kidney Int. 1988;3:900-911.
38. Appel GB. Aminoglycoside nephrotoxicity. Am J Med. 1990;88:3S-16S.
39. Smith CR, Moore RD, Lietman PS. Risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis. 1986;8:308-313.
40. Prins JM, Buller HRK, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993;341:335-339.
41. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993; 44:643-653.
42. Blackshear JL, Davidman M, Stillman MT. Identification of risk for renal insufficiency from non-steroidal anti-inflammatory drugs. Arch Intern Med. 1983;143:1130-1134.
43. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31:588-598.
44. Bunning RD, Barth WF. Sulindac: a potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA. 1982;248:2864-2867.
45. Whelton A, Stout RL, Spilman PS, Kiassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure: a prospective, randomized, crossover comparison. Ann Intern Med. 1990;112:568-576.
46. Weisberg LS, Kurnik PB, Kurnik BRC. Risk of radio contrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45: 259-265.
47. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. N Engl J Med. 1989;320:143-153.
48. Weinrauch LA, Haely RW, Leland OS, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. Ann Intern Med. 1977;86:55-59.
49. van Zee BE, Hoy WE, Talley TE, Jaenike JR. Renal injury associated with intravenous pyelography in nondiabetic and diabetic patients. Ann Intern Med. 1978;89:51-54.
50. D'Elia JA, Gleason RE, Alday M, et al. Nephrotoxicity from angiographic contrast material: a prospective study. Am J Med. 1982;72:719-724.
51. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and non ionic contrast media in 1196 patients: a randomized trial. Kidney Int. 1995;47:254-261.
52. Solomon R, Werner C, Mann D, D'Elia JA, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radio contrast agents. N Engl J Med. 1994;331: 1416-1420.
53. Jacobson HR. Ischemic renal disease: an overlooked clinical entity? Kidney Int. 1988;34:729-743.
54. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med. 1993;118:712-719.
55. Hricik DE, Dunn MJ. Angiotensin converting enzyme inhibitor induced renal failure: causes consequences and diagnostic uses. J Am Soc Nephrol. 1990;1:845-858.
56. Messina LM, Zelenock GB, Yao KA, Stanley JC. Renal revascularization for recurrent pulmonary edema in patients with poor controlled hypertension and renal insufficiency: a distinct subgroup of patients with arteriosclerotic renal artery occlusive disease. J Vasc Surg. 1992;15: 73-82.
57. Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularization. Lancet. 1988;2:551-552.
58. Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. Arch Surg. 1981;116:1408-1415.
59. Schreiber MI, Pohl MA, Novick M. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984;11:327-331.
60. Strandness DE. Natural history of renal artery stenosis. Am J Kidney Dis. 1994;24:630-635.
61. Schreiber MJ, Pohl MA, Novick M. Preserving renal function by revascularization. Annu Rev Med. 1990;41:423-429.
62. Ying CY, Tifft CP, Gavras H, Chobanian AV. Renal revascularization in the azotemic hypertensive patient resistant to therapy. N Engl J Med. 1984;311:1070-1075.
63. Brenner BM, Mayer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease. N Engl J Med. 1982;307:652-659.
64. Klahr S, Schreiner GF, Ichikawa I. The progression of renal disease. N Engl J Med. 1988;318: 1657-1666.
65. Baldwin DS, Neugarten J. Blood pressure control and renal insufficiency. In: Mitch WE, Brenner BM, Stein JH, eds. The Progressive Nature of Renal Disease. New York, NY: Churchill Livingstone Inc; 1986:81-110.
66. Klahr S. The kidney in hypertension: villain and victim. N Engl J Med. 1989;320:731-733.
67. Klahr S, Buerkert J, Pukerson ML. Role of dietary factors in the progression of chronic renal disease. Kidney Int. 1983;24:579-587.
68. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development of long term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
69. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis. 1995;25:103-106.
70. Smith MC, Dunn MJ. Hypertension in renal parenchymal disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1995:2081-2102.
71. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670-674.
72. Hostetter TH, Olson JL, Rennke HJ, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93.
73. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes versus hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989; 35:654-660.
74. Zucchelli P, Zuccala A, Borghi M, et al. Long term comparison between captopril and nifedepine in the progression of renal insufficiency. Kidney Int. 1992;42:452-458.
75. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria and progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
76. Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis. 1993;22:188-195.
77. Wright JT Jr, Kusek JW, Toto RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot study. Control Clin Trial. 1996;17:35-65.
78. Hosteller TH, Mayer TW, Rennke HJ. Chronic effects of dietary protein on renal structure and function in the rat with intact and reduced renal mass. Kidney Int. 1986;30:509-517.
79. Nath KA, Kren SM, Hostetter TH. Dietary protein restriction in established injury in the rat. J Clin Invest. 1986;78:1199-1205.
80. Locatelli F, Alberti F, Graziani G, Buccianti G, Redaelli B, Giangrande A. Prospective randomized multicenter trial of effect of protein restriction on progression of chronic renal insufficiency. Lancet. 1991;337:1299-1304.
81. Williams PS, Stevens ME, Fass G, Irons L, Bone JM. Failure of dietary protein and phosphate restriction to retard the progression of chronic renal failure: a prospective randomized controlled trial. QJM. 1991;81:837-855.
82. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin dependent diabetes mellitus. N Engl J Med. 1991;324:78-84.
83. Ihle BU, Beck GJ, Whitworth JA, Charlwood RA, Kincaid-Smith P. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med. 1989;321:1773-1777.
84. Pedrini T, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non diabetic renal diseases: a meta-analysis. Ann Intern Med. 1996;124:627-632.
85. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884.
86. Ikizler TA, Greene JH, Wingard RL, Parker RA, Hakim RM. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol. 1995;6:1386-1391.
87. Krolewski AS, Warram AS, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med. 1985; 78:785-794.
88. Anderson AR, Christiansen JS, Anderson JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 insulin dependent diabetes: an epidemiologic study. Diabetologica. 1983;25:496-501.
89. Sirmon MD. Renal disease in noninsulin dependent diabetes mellitus. Am J Med Sci. 1990;300: 388-395.
90. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin dependent diabetes mellitus. N Engl J Med. 1988;318:140-145.
91. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin dependent diabetics. BMJ. 1987;295:515-517.
92. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy: an eight-year prospective study. Kidney Int. 1992;41:822-828.
93. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med. 1984;310:356-360.
94. Reichard P, Nilsson B, Rosenquist U. The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
95. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-1462.
96. Kasiske BL, Roberto SN, Ma JZ, Kiao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118: 129-138.
97. Mathiesen EF, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-87.
98. Greger R, Heidland A. Action and clinical use of diuretics. In: Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E, eds. Oxford Textbook of Clinical Nephrology. New York, NY: Oxford University Press Inc; 1992:197-223.
99. Fliser D, Schroter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46:482-488.
100. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC. Loop diuretics for chronic renal insufficiency: a continuous infusion is more effective than bolus therapy. Ann Intern Med. 1991; 115:360-366.
101. Smith MC, Dunn MJ. Hypertension associated with renal parenchymal disease. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. Boston, Mass: Little Brown & Co; 1997:1333-1365.
102. Abraham PA, Opsahl JA, Halstenson CE, Keane WE. Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. Arch Intern Med. 1988;148:2358-2362.
103. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med. 1986;146:2145-2148.
104. Donohue JF, Kelly J, Laher MS, Doyle GD. Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med. 1988; 85:31-34.
105. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch Intern Med. 1994;154:1185-1202.
106. Converse RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
107. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127:337-345.
108. Porush JG. Hypertension and chronic renal failure: the use of ACE inhibitors. Am J Kidney Dis. 1998;31:177-184.
109. Ritz E. Are antihypertensive drugs similar in protecting the kidney? Am J Hypertens. 1995;8: 535-585.
110. Mackenzie HS, Brenner BM. Current strategies for retarding the progression of renal disease. Am J Kidney Dis. 1998;31:161-170.
111. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155:1073-1080.
112. Ruggenenti P, Mosconi L, Bianchi L, et al. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin dependent diabetic patients. Am J Kidney Dis. 1994;24:753-761.
113. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996; 45:216-222.
114. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334.939-945.
115. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincald-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency. Am J Kidney Dis. 1996;27:489-495.
116. The GISEN Group. Randomized placebo-controlled trial of effect of rampril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet. 1997;349:1857-1863.
117. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
118. Björck S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ. 1990;300:904-907.
119. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ. 1986; 293:471-474.
120. Björck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339-343.
121. Schon DA, Silva P, Hayslett JP. Mechanism of potassium excretion in renal insufficiency. Am J Physiol. 1974;227:1323.
122. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug induced hyperkalemia. Medicine. 1985; 64:357-370.
123. DeFronzo RA, Sherwin RS, Dillingham M. Influence of basal insulin and glucagon secretion on potassium and sodium metabolism: studies with somatostatin in normal dogs and normal and diabetic human beings. J Clin Invest. 1978;61:472.
124. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333:166-174.
125. Delmez JA, Slatopolsky E. Renal osteodystrophy: pathogenesis and treatment. Kidney. 1990; 22:1-8.
126. Bushinsky DA. Bone disease in moderate renal failure: cause, nature and prevention. Annu Rev Med. 1997;48:167-176.
127. Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidiol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310:358-363.
128. Felsenfeld M. Considerations for the treatment of secondary hyperparathyroidism in renal failure. J Am Soc Nephrol. 1997;8:993-1004.
129. Warnock DG. Uremic acidosis. Kidney Int. 1988; 34:278-287.
130. Schwartz WE, Hall PWI, Hays RM, Relman AS. On the mechanism of acidosis in chronic renal disease. J Clin Invest. 1959;38:39-52.
131. van Slyke DD, Linder GC, Hiller A, Leiter L, McIntosh JF. The excretion of ammonia and titratable acid in nephritis. J Clin Invest. 1926;2:225-239.
132. Eschbach JW, Adamson JW. Anemia of endstage renal disease. Kidney Int. 1985;28:1-5.
133. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35:134-148.
134. Shaw AB. Haemolysis in chronic renal failure. BMJ. 1967;213-216.
135. Zappacosta AR, Perras ST, Bell A. Weekly subcutanoeus recombinant erythropoeitin corrects anemia of progressive renal failure. Am J Med. 1991;91:229-232.
136. Kieinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abeis RI. The use of recombinant human erythropoeitin in the correction of anemia in predialysis and its effect on renal function: a double blind, placebo-controlled trial. Am J Kidney Dis. 1989;14:486-495.
137. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoeitin treatment in predialysis patients: a double blind placebo controlled trial. Ann Intern Med. 1989;110:108-114.
138. Fellner SF, Lang RM, Neumann A, Korcarz C, Borow KM. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int. 1993;44:1309-1315.
139. Beusterien KM, Nissensen AR, Port FK, Kelly M, Steinwald S, Ware JE. The effects of recombinant human erythropoeitin on functional health and well being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763-773.
140. Raine AEG, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis. 1991;18: 76-83.
141. Aronoff GR, Abel SR. Practical guidelines for drug dosing in patients with renal impairment. In: Schrier RW, ed. Manual of Nephrology. Boston, Mass: Little Brown & Co; 1995:173-185.
142. Bennett WM, Aronoff GR, Golper TA. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. Philadelphia, Pa: American College of Physicians; 1994.
143. Owen WE, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329:1001-1006.
144. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis. 1992;19:303-317.
145. Kopple JD, Monteon FJ, Shaib JK. Effect of energy intake on nitrogen metabolism in non dialyzed patients in chronic renal failure. Kidney Int. 1986;29:734-742.
146. Broyer M, Ehrich J, Jones E, Selwood N. Five year survival of kidney transplantation in children: data from the European registry (EDTA-ERA). Kidney Int. 1993;43(suppl):522-525.
147. US Renal Data System. USRDS 1997 Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1997.